IVIEW Therapeutics is a clinical-stage biotechnology company focusing on innovative ophthalmic therapeutics. Founded in 2015 by Bo Liang and John Baldwin, the company is based in Cranbury, New Jersey. As of the latest updates, it specializes in developing treatments for eye diseases like dry eye, myopia, and conjunctivitis, utilizing novel mechanisms and drug delivery technologies. IVIEW Therapeutics has raised approximately $55 million in funding across multiple rounds.
Attribute | Information |
---|---|
Founding Date | 2015 |
Headquarters | Cranbury, New Jersey, USA |
Founders | Bo Liang, John Baldwin |
Revenue | Not yet generating sales revenue |
Profits | Not applicable (Development stage) |
Key Investors | BioAdvance, Proxima Ventures |
Industry | Biotechnology, Ophthalmology |
Number of Employees | Approximately 6 (as of December 2021) |
Major Product Candidates | IVVIEW-1201, IVVIEW-1501, IVVIEW-1301 |
IVIEW Therapeutics was established in 2015 with a focus on developing novel ophthalmic therapeutics. Initial projects included IVIEW-1201 and IVIEW-1501, targeting conjunctivitis and sinusitis respectively. The company gained attention following a successful funding round led by BioAdvance and Proxima Ventures. Early development was marked by strategic formulation innovations and extensive preclinical trials aimed at addressing unmet medical needs in eye care. These efforts laid a foundation that set the stage for future clinical trials and IND applications.
IVIEW Therapeutics operates with a strategic focus on advancing therapeutic solutions for ocular diseases through innovative drug delivery systems. Key achievements include:
IVIEW Therapeutics is actively conducting clinical trials and advancing its pipeline of innovative ophthalmic solutions. Its operations focus heavily on clinical-stage development with a robust portfolio that includes small molecules and potential gene therapies. The company differentiates itself with a unique drug delivery technology platform and a focus on novel mechanisms that address significant unmet needs in the ophthalmic sector.
IVIEW Therapeutics stands out in the biotechnology landscape for its dedicated approach to innovation in ophthalmic care. With ongoing clinical trials and a strategic emphasis on groundbreaking drug delivery methods, the company is poised to revolutionize treatment paradigms for ocular diseases. Continuous investor support and promising product pipelines indicate a strong potential for future contributions to eye care therapeutics, positioning IVIEW as a key player in its industry.